Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Inkjet-printed electrochemically reduced graphene oxide microelectrode as a platform for HT-2 mycotoxin immunoenzymatic biosensing

  • Kudr, Jiri|||0000-0002-2058-4563
  • Zhao, Lei|||0000-0003-0291-2655
  • Nguyen, Emily P.|||0000-0003-4299-2055
  • Arola, Henri
  • Nevanen, Tarja K.
  • Adam, Vojtech
  • Zitka, Ondrej
  • Merkoçi, Arben|||0000-0003-2486-8085
The design and application of an inkjet-printed electrochemically reduced graphene oxide microelectrode for HT-2 mycotoxin immunoenzymatic biosensing is reported. A water-based graphene oxide ink was first formulated and single-drop line working microelectrodes were inkjet-printed onto poly(ethylene 2,6-naphthalate) substrates, with dimensions of 78 μm in width and 30 nm in height after solvent evaporation. The printed graphene oxide microelectrodes were electrochemically reduced and characterized by Raman and X-ray photoelectron spectroscopies in addition to microscopies. Through optimization of the electrochemical reduction parameters, differential pulse voltammetry were performed to examine the sensing of 1-naphthol (1-N), where it was revealed that reduction times had significant effects on electrode performance. The developed microelectrodes were then used as an immunoenzymatic biosensor for the detection of HT-2 mycotoxin based on carbodiimide linking of the microelectrode surface and HT-2 toxin antigen binding fragment of antibody (anti-HT2 (10) Fab). The HT-2 toxin and anti-HT2 (10) Fab reaction was reported by anti-HT2 immune complex single-chain variable fragment of antibody fused with alkaline phosphatase (anti-IC-HT2 scFv-ALP) which is able to produce an electroactive reporter - 1-N. The biosensor showed detection limit of 1.6 ng ∙ mL¯¹ and a linear dynamic range of 6.3 - 100.0 ng ∙ mL¯¹ within a 5 min incubation with 1-naphthyl phosphate (1-NP) substrate.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Nanomaterials for nanotheranostics, tuning their properties according to disease needs

  • Wong, Xin Yi
  • Sena-Torralba, Amadeo|||0000-0003-1340-1383
  • Álvarez Diduk, Ruslan|||0000-0002-9876-1574
  • Muthoosamy, Kasturi
  • Merkoçi, Arben|||0000-0003-2486-8085
Nanotheranostics is one of the biggest scientific breakthroughs in nanomedicine. Most of the currently available diagnosis and therapies are invasive, time-consuming, and associated with severe toxic side effects. Nanotheranostics, on the other hand, has the potential to bridge this gap by harnessing the capabilities of nanotechnology and nanomaterials for combined therapeutics and diagnostics with markedly enhanced efficacy. However, nanomaterial applications in nanotheranostics are still in its infancy. This is due to the fact that each disease has a particular microenvironment with well-defined characteristics, which promotes deeper selection criteria of nanomaterials to meet the disease needs. In this review, we have outlined how nanomaterials are designed and tailored for nanotheranostics of cancer and other diseases such as neurodegenerative, autoimmune (particularly on rheumatoid arthritis), and cardiovascular diseases. The penetrability and retention of a nanomaterial in the biological system, the therapeutic strategy used, and the imaging mode selected are some of the aspects discussed for each disease. The specific properties of the nanomaterials in terms of feasibility, physicochemical challenges, progress in clinical trials, its toxicity, and their future application on translational medicine are addressed. Our review meticulously and critically examines the applications of nanotheranostics with various nanomaterials, including graphene, across several diseases, offering a broader perspective of this emerging field.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Lateral flow assay modified with time-delay wax barriers as a sensitivity and signal enhancement strategy

  • Sena-Torralba, Amadeo|||0000-0003-1340-1383
  • Ngo, Duy Ba
  • Parolo, Claudio|||0000-0001-9481-4408
  • Hu, Liming|||0000-0002-8666-9287
  • Álvarez Diduk, Ruslan|||0000-0002-9876-1574
  • Bergua Canudo, José Francisco|||0000-0002-5969-193X
  • Rosati, Giulio|||0000-0002-0227-4561
  • Surareungchai, Werasak
  • Merkoçi, Arben|||0000-0003-2486-8085
The ease of use, low cost and quick operation of lateral flow assays (LFA) have made them some of the most common point of care biosensors in a variety of fields. However, their generally low sensitivity has limited their use for more challenging applications, where the detection of low analytic concentrations is required. Here we propose the use of soluble wax barriers to selectively and temporarily accumulate the target and label nanoparticles on top of the test line (TL). This extended internal incubation step promotes the formation of the immune-complex, generating a 51.7-fold sensitivity enhancement, considering the limit of quantification, and up to 96% signal enhancement compared to the conventional LFA for Human IgG (H-IgG) detection.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Paper-based electrophoretic bioassay, biosensing in whole blood operating via smartphone

  • Sena-Torralba, Amadeo|||0000-0003-1340-1383
  • Álvarez Diduk, Ruslan|||0000-0002-9876-1574
  • Parolo, Claudio|||0000-0001-9481-4408
  • Torné-Morató, Helena
  • Müller, Alexander
  • Merkoçi, Arben|||0000-0003-2486-8085
Point-of-care (PoC) tests are practical and effective diagnostic solutions for major clinical problems, ranging from the monitoring of a pandemic to recurrent or simple measurements. Although, in recent years, a great improvement in the analytical performance of such sensors has been observed, there is still a major issue that has not been properly solved: The ability to perform adequate sample treatments. The main reason is that normally sample treatments require complicated or long procedures not adequate for deployment at the PoC. In response, a sensing platform, called paperbased electrophoretic bioassay (PEB), that combines the key characteristics of a lateral flow assay (LFA) with the sample treatment capabilities of electrophoresis is developed. In particular, the ability of PEB to separate different types of particles and to detect human antibodies in untreated spiked whole blood is demonstrated. Finally, to make the platform suitable for PoC, PEB is coupled with a smartphone that controls the electrophoresis and reads the optical signal generated. It is believed that the PEB platform represents a much-needed solution for the detection of low target concentrations in complex media, solving one of the major limitations of LFA and opening opportunities for point-of-care sensors.